GlassScriptPhysician profile
Morgan Drake
NPI 1285476861
$1,990.57
in general payments reported to CMS, 2019-2025
37 companies · $1,273 in 2025
The $1,273 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $718 · 2025: $1,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,898 · Education: $92.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,898.09 |
| Education | $92.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $199.35 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $184.67 | 2025 | Carvykti, Rybrevant, Erleada |
| Lilly USA, LLC | $169.12 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Puma Biotechnology, INC. | $141.43 | 2025 | |
| Tempus Ai, INC | $124.80 | 2024 | |
| Blueprint Medicines Corporation | $118.68 | 2024 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $97.17 | 2024-2025 | |
| Abbvie INC. | $77.98 | 2024-2025 | |
| Sobi, INC | $59.00 | 2024-2025 | |
| Beone Medicines USA, INC. | $57.33 | 2025 | Brukinsa, Tevimbra |
| Jazz Pharmaceuticals INC. | $52.44 | 2024-2025 | |
| Emd Serono, INC. | $50.27 | 2024-2025 | |
| Geron Corporation | $46.80 | 2025 | Rytelo |
| Genzyme Corporation | $46.37 | 2024-2025 | |
| Incyte Corporation | $44.38 | 2025 | Jakafi, Monjuvi |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $41.55 | 2025 | Datroway, Enhertu |
| Taiho Oncology, INC. | $40.72 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.84 | 2025 | Fruzaqla, Iclusig |
| Caris Mpi, INC. | $34.76 | 2025 | Mi Cancer Seek |
| Regeneron Healthcare Solutions, INC. | $34.42 | 2024-2025 | Libtayo |
| Genentech USA, INC. | $29.18 | 2024-2025 | Tecentriq Hybreza, Alecensa, Tecentriq |
| Eisai INC. | $25.60 | 2025 | |
| Aveo Pharmaceuticals, INC. | $24.32 | 2025 | |
| Genmab U.S., INC. | $22.70 | 2024 | Epkinly |
| Stemline Therapeutics INC. | $22.59 | 2025 | Orserdu |
| Spectrum Pharmaceuticals INC. | $22.43 | 2024 | Rolvedon |
| Kyowa Kirin, INC. | $20.71 | 2025 | |
| Immunocore Limited | $20.58 | 2025 | Kimmtrak |
| Gilead Sciences, INC. | $19.37 | 2024 | |
| Karyopharm Therapeutics INC. | $18.70 | 2024 | Xpovio |
| Adc Therapeutics America, INC. | $16.68 | 2025 | |
| Tersera Therapeutics LLC | $16.24 | 2025 | Zoladex |
| Bayer Healthcare Pharmaceuticals INC. | $15.77 | 2025 | |
| Glaxosmithkline, LLC. | $14.68 | 2025 | Ojjaara |
| Ipsen Biopharmaceuticals, INC | $14.52 | 2025 | Onivyde |
| Acrotech Biopharma INC. | $13.86 | 2025 | Beleodaq |
| Beigene USA, INC. | $13.56 | 2024 | Tevimbra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Drake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.